Virtual Exhibit Hall


There can be many challenges - physically, financially, and emotionally - faced every day by people living with diseases of the central nervous system and their families. Neurodegenerative conditions and movement disorders such as multiple sclerosis (MS), Parkinson’s Disease (PD), Huntington’s Disease (HD) and Tardive Dyskinesia (TD) affect every aspect of life, with even the most mundane tasks requiring great courage and effort. It is expected that by 2030, we will see a rise of between 30-50% in the incidence of such diseases, with an associated need for increased treatment and care. Teva provides a number of products to treat patients with neurological and neurodegenerative disorders – with a focus on helping patients manage their condition.


Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids*, as well as over a dozen mid-to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.  For more information, visit neurocrine.com, and follow the company on LinkedInTwitter and Facebook. (*in collaboration with AbbVie)

Founded in 1978, HPCCR provides compassionate care to individuals with life-limiting and terminal illnesses; serving 31 counties from 13 regional locations in North & South Carolina.  The mission of Hospice & Palliative Care Charlotte Region is to relieve suffering and improve the quality and dignity of life through compassionate hospice care for those at the end of life, palliative care for those with advanced illness, and through community education. For more information, call 704.375.0100, or visit HPCCR online at hpccr.org.

We have a specialized Huntington's Disease Unit that provides around the clock service here at Leisure Chateau. We are proud to be one of the specialized units in the country that provide care uniquely tailored to the needs of the individual with Huntington's Disease.As a host to the largest Huntington Disease population throughout New Jersey, Leisure Chateau has pioneered and developed a unique care and activity program geared specifically for our Huntington Disease residents.

HDYO is an international foundation supporting, educating, and empowering young people up to 35 years, impacted by Huntington's Disease (HD).

PREVENT-HD (formerly known as PREDICT-HD) invites volunteers to participate in a research study to help develop and refine the tools that can be used in clinical trials to measure the effectiveness of treatment before the disease impacts daily life. We want to build a case for testing these treatments much earlier in people at risk for HD. Starting treatment sooner may help delay the start of symptoms or slow down the progression of the disease.

We are currently enrolling adults from HD families. Criteria includes:

  • People who have been gene tested for HD, who carry or do not carry the HD gene
  • People who have recently been diagnosed with HD and are in the very early stages of the disease
  • People who are gene-positive, but are not currently showing any symptoms (pre-symptomatic)

uniQure is delivering on the promise of gene therapy – single treatments with potentially transformative results. We are utilizing our technology to advance a pipeline of gene therapies to treat patients with neurodegenerative diseases, and other severe genetic diseases. We are currently conducting a phase 1/2 trial in Huntington’s disease, the first gene therapy ever in a clinical trial for HD. Our most advance program is a phase 3 clinical trial in hemophilia B. 

Our clinic provides care to those who are living with Huntington's disease or who are at risk for the disease. We are North Carolina’s only nationally designated Huntington’s Disease Society of America (HDSA) Center of Excellence, which recognizes expertise in diagnosing and managing Huntington’s disease. Our comprehensive team includes movement disorders specialists; physical, occupational, and speech therapists; clinical social workers; a clinical pharmacist; nurses, and others who work together to provide comprehensive care to patients and families at any stage of Huntington’s disease. 

Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with better brain health. Our mission is to pioneer solutions to deliver life-changing brain health medicines, so every person can thrive. 

HD Reach is working to improve the care and quality of life of those affected by Huntington’s disease. Founded as a nonprofit in 2009, we provide connections to medical providers, referrals to local services, care management, family support, education, and anonymous genetic testing.

This conference is made possible by our generous sponsors: